61
Participants
Start Date
January 31, 2012
Primary Completion Date
September 30, 2016
Study Completion Date
September 30, 2016
SAR3419
"Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous"
Investigational Site Number 056001, Leuven
Investigational Site Number 056002, Ghent
Investigational Site Number 203003, Prague
Investigational Site Number 203001, Prague
Investigational Site Number 380001, Milan
Investigational Site Number 380002, Bergamo
Investigational Site Number 380006, Pavia
Investigational Site Number 724001, Madrid
Investigational Site Number 380008, Mestre
Investigational Site Number 840003, Augusta
Investigational Site Number 792003, Izmir
Investigational Site Number 792001, Izmir
Investigational Site Number 380004, Bologna
Investigational Site Number 380007, Modena
Investigational Site Number 724003, Valencia
Investigational Site Number 376002, Tel Litwinsky
Investigational Site Number 203002, Brno
Investigational Site Number 840001, Denver
Investigational Site Number 840005, Boise
Investigational Site Number 380003, Palermo
Investigational Site Number 376003, Jerusalem
Investigational Site Number 616003, Brzozów
Investigational Site Number 616002, Kielce
Investigational Site Number 616001, Warsaw
Investigational Site Number 724002, Barcelona
Investigational Site Number 724004, Barcelona
Investigational Site Number 826001, Leicester
Investigational Site Number 826002, Manchester
Lead Sponsor
Sanofi
INDUSTRY